Milestone Group Inc. acquired a new stake in Eli Lilly and Company (NYSE:LLY) during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 2,532 shares of the company’s stock, valued at approximately $213,000.
Other hedge funds have also recently made changes to their positions in the company. Assetmark Inc. raised its stake in shares of Eli Lilly and by 226.1% in the first quarter. Assetmark Inc. now owns 12,913 shares of the company’s stock valued at $1,086,000 after buying an additional 8,953 shares in the last quarter. HL Financial Services LLC raised its stake in shares of Eli Lilly and by 15.8% in the first quarter. HL Financial Services LLC now owns 93,272 shares of the company’s stock valued at $7,845,000 after buying an additional 12,735 shares in the last quarter. Quantitative Investment Management LLC bought a new stake in shares of Eli Lilly and during the first quarter valued at approximately $5,601,000. Twin Capital Management Inc. raised its stake in shares of Eli Lilly and by 297.7% in the first quarter. Twin Capital Management Inc. now owns 44,380 shares of the company’s stock valued at $3,733,000 after buying an additional 33,220 shares in the last quarter. Finally, Norinchukin Bank The increased its position in shares of Eli Lilly and by 5.0% in the first quarter. Norinchukin Bank The now owns 115,527 shares of the company’s stock valued at $9,717,000 after buying an additional 5,480 shares during the last quarter. 75.61% of the stock is currently owned by institutional investors.
Shares of Eli Lilly and Company (NYSE LLY) traded down 0.12% during trading on Tuesday, hitting $81.97. The stock had a trading volume of 3,292,993 shares. Eli Lilly and Company has a 52 week low of $64.18 and a 52 week high of $86.72. The company has a market capitalization of $86.48 billion, a price-to-earnings ratio of 35.47 and a beta of 0.34. The company’s 50 day moving average price is $83.03 and its 200 day moving average price is $81.54.
Eli Lilly and (NYSE:LLY) last posted its quarterly earnings results on Tuesday, July 25th. The company reported $1.11 EPS for the quarter, topping analysts’ consensus estimates of $1.05 by $0.06. Eli Lilly and had a net margin of 11.12% and a return on equity of 28.71%. The company had revenue of $5.82 billion for the quarter, compared to analysts’ expectations of $5.60 billion. During the same quarter in the previous year, the firm posted $0.86 EPS. Eli Lilly and’s revenue was up 7.8% on a year-over-year basis. Analysts predict that Eli Lilly and Company will post $4.16 earnings per share for the current year.
The firm also recently announced a quarterly dividend, which will be paid on Friday, September 8th. Shareholders of record on Tuesday, August 15th will be issued a dividend of $0.52 per share. The ex-dividend date of this dividend is Friday, August 11th. This represents a $2.08 dividend on an annualized basis and a yield of 2.54%. Eli Lilly and’s payout ratio is 90.04%.
Several equities analysts have issued reports on the company. Berenberg Bank reiterated a “buy” rating and issued a $98.00 price objective on shares of Eli Lilly and in a research report on Friday. BMO Capital Markets restated a “sell” rating and set a $73.00 target price on shares of Eli Lilly and in a research report on Friday. TheStreet upgraded Eli Lilly and from a “c+” rating to a “b+” rating in a research report on Tuesday, July 25th. UBS AG downgraded Eli Lilly and to a “hold” rating and set a $85.00 target price for the company. in a research report on Wednesday, July 26th. Finally, Oppenheimer Holdings, Inc. downgraded Eli Lilly and from an “outperform” rating to a “market perform” rating and set a $90.00 target price for the company. in a research report on Wednesday, July 26th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating and twelve have given a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of $88.27.
In other news, VP Michael J. Harrington sold 22,833 shares of the company’s stock in a transaction on Friday, June 9th. The shares were sold at an average price of $79.97, for a total value of $1,825,955.01. Following the transaction, the vice president now owns 62,056 shares of the company’s stock, valued at $4,962,618.32. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, major shareholder Lilly Endowment Inc sold 220,000 shares of the company’s stock in a transaction on Monday, July 31st. The stock was sold at an average price of $83.09, for a total transaction of $18,279,800.00. Following the completion of the transaction, the insider now directly owns 124,049,283 shares in the company, valued at approximately $10,307,254,924.47. The disclosure for this sale can be found here. Insiders have sold a total of 669,733 shares of company stock worth $55,845,287 in the last three months. Insiders own 0.20% of the company’s stock.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.
Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with our FREE daily email newsletter.